Bris­tol My­ers spells out Op­di­vo win in melanoma — how does it stack up against Keytru­da?

Bris­tol My­ers Squibb is ready for a da­ta show­down with Mer­ck as they move their re­spec­tive PD-1 in­hibitors in­to ear­li­er lines of melanoma treat­ment.

Tak­ing the stage at the an­nu­al meet­ing of the So­ci­ety for Melanoma Re­search, Bris­tol My­ers re­port­ed that in the Phase III Check­Mate-76K tri­al, Op­di­vo re­duced the risk of re­cur­rence or death by 58% — trans­lat­ing to a haz­ard ra­tio of 0.42 on the pri­ma­ry end­point of re­cur­rence-free sur­vival (p < 0.0001).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.